Investment analysts at Bank of America initiated coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a report released on Tuesday, The Fly reports. The brokerage set a “buy” rating on the stock.

Several other equities analysts have also recently issued reports on YMAB. BTIG Research started coverage on shares of Y-mAbs Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $35.00 price objective on the stock. Cowen reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Tuesday. Finally, Canaccord Genuity assumed coverage on shares of Y-mAbs Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $30.00 price objective on the stock.

Shares of YMAB opened at $21.60 on Tuesday. Y-mAbs Therapeutics has a 12-month low of $20.03 and a 12-month high of $31.00.

In other news, CEO Moller San Pedro Claus Juan bought 31,250 shares of the company’s stock in a transaction dated Tuesday, September 25th. The shares were acquired at an average cost of $16.00 per share, with a total value of $500,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director James Healy bought 500,000 shares of the company’s stock in a transaction dated Friday, September 21st. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $8,000,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders bought 961,424 shares of company stock worth $15,382,784.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Story: Market Capitalization

The Fly

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.